Elevance Health Inc. closed 31.17% below its 52-week high of $567.26, which the company reached on September 3rd.
Wall Street analysts forecast that Elevance Health (ELV) will report quarterly earnings of $3.82 per share in its upcoming release, pointing to a year-over-year decline of 32%.
Financial writer recommends buying Elevance Health stock despite recent drop, citing strong industry trends and potential for significant upside.
Elevance Health (NYSE:ELV – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a ...
Health insurance provider Elevance Health (NYSE:EVH) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 6.6% year on year to $45.44 billion. Its non-GAAP profit of $3.84 per ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurosense Therapeutics Ltd. (NRSN – Research Report), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback